CH DUNKERQUE Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2015
NCT02197221
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

CH Dunkerque | HOSPITAL CENTER DUNKERQUE

Active Ingredients

Drugs in Phase 3 Trials (4)

bortezomib (velcade) (1 trial)

melphalan (alkeran) (1 trial)

propofol (diprivan) (1 trial)

sevoflurane (ultane) (1 trial)

Drugs in Other Trials (2)

aminoven (1 trial)

renoral (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Lung Injury (Phase 3)

Multiple Myeloma (Phase 3)

Neoplasms, Plasma Cell (Phase 3)

Respiratory Distress Syndrome (Phase 3)

Respiratory Distress Syndrome, Newborn (Phase 3)

Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 6